{"id":195037,"name":"ASTELLAS PHARMA US, INC.","slug":"astellas-pharma-us-inc","state":"IL","description":"pharmaceutical company","totalSpending":1480000,"filings":27,"yearlySpending":[{"year":2018,"income":200000},{"year":2019,"income":250000},{"year":2020,"income":250000},{"year":2021,"income":240000},{"year":2022,"income":240000},{"year":2023,"income":240000},{"year":2024,"income":60000}],"firms":["ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)"],"lobbyists":["VINCENT ROBERTI, SR.","STEVEN IRIZARRY","LYDIA STRUNK"],"issues":["HCR","FOR","MMM","LAW","BUD",null],"sampleDescriptions":["- Issues related to the Bayh-Dole Act (Pub. L. 96-517)\n- Issues related to drug pricing and value, generally\n- Issues related to the importation of prescription medicines, generally","- Issues related to lobbying disclosure for US affiliates in the Disclosing Foreign Influence Act (H.R.4170/S. 2039) and Foreign Agents Registration Amendments Act (S. 2482)","- Issues related to Medicare Part B (HOPPS), generally\n- Issues related to Medicare Part D; the Bipartisan Budget Act (H.R. 1892); and the Consolidated Appropriations Act (H.R. 1625)\n- Issues related to the repeal of the Independent Payment Advisory Board (IPAB); Protecting Seniors' Access to Medicare Act of 2017 (H.R. 849/S. 260); Protecting Medicare from Executive Action Act of 2017 (S. 251)","\"Issues related to lobbying disclosure for US affiliates in the Disclosing Foreign Influence Act (H.R.4170/S. 2039) and Foreign Agents Registration Amendments Act (S. 2482)\"","Issues related to Medicare Part D","HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs. \nIssues related to the Bayh-Dole Act (Pub. L. 96-517)\nIssues related to drug pricing and value, generally\nPandemic and All-Hazards Preparedness and Advancing Innovation Act (PAHPA) (S. 2852/H.R. 6378) \nIssues related to the importation of prescription medicines, generally","HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs\nIssues related to march-in rights under the Bayh-Dole Act (Pub. L. 96-517)\nIssues related to drug pricing and value, generally\nPandemic and All-Hazards Preparedness and Advancing Innovation Act (PAHPA)\nIssues related to the importation of prescription medicines, generally","Issues related to lobbying disclosure for US affiliates","Issues related to Medicare Part D, generally","House and Senate Appropriations for FY ending Sept. 30, 2019","HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs\nIssues related to march-in rights under the Bayh-Dole Act (Pub. L. 96-517)\nIssues related to drug pricing and value, generally","Issues related to Medicare Part D, including non-interference, rebate policy issues\nIssues related to drug pricing, value, and transparency, generally","Issues related to Medicare Part D, including reforms, non-interference, rebate policy issues\nIssues related to drug pricing, value, and transparency, generally","House and Senate Appropriations for FY 2021","Medicare prompt pay discount exclusion, including legislation to ensure appropriate reimbursement for drugs and biologics under Medicare Part B by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's Average Sales Price (ASP).\nASP, generally\nMedicare Part D, including removal of safe harbor protection for drug rebates\nMedicare Part B, including proposals to create an international pricing index and establish a competitive acquisition program\nPrescription Drug Pricing Reduction Act (S. 2543); inclusion of bona fide service fees in ASP calculation under Medicare Part B.\nS. 988 and H.R. 803; legislation to prohibit prescription drug plan sponsors and MAPD organizations under Medicare program from retroactively reducing payment on clean claims submitted by pharmacies.","Issues related to march-in rights under the Bayh-Dole Act (Pub. L. 96-517)\nIssues related to drug pricing and value, generally","Issues related to march-in rights under the Bayh-Dole Act (Pub. L. 96-517)\nIssues related to drug pricing and value, generally\nIssues related to biopharmaceutical supply chain, generally","Issues related to march-in rights under the Bayh-Dole Act (Pub. L. 96-517) Issues related to drug pricing and value, generally Issues related to biopharmaceutical supply chain, generally","Issues related to Medicare Part D, including reforms, non-interference, rebate policy issues Issues related to drug pricing, value, and transparency, generally","Issues related to march-in rights under the Bayh-Dole Act (Pub. L. 96-517) Women's health issues; WARM Act (H.R. 6743)"],"years":[2018,2019,2020,2021,2022,2023,2024]}